Literature DB >> 5683827

Lysostaphin: an enzymatic approach to staphylococcal disease. 3. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice.

R E Dixon, J S Goodman, M G Koenig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5683827      PMCID： PMC2591441     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN： 0044-0086


× No keyword cloud information.
  11 in total

1.  PURIFICATION AND PROPERTIES OF LYSOSTAPHIN--A LYTIC AGENT FOR STAPHYLOCOCCUS AUREUS.

Authors:  C A SCHINDLER; V T SCHUHARDT
Journal:  Biochim Biophys Acta       Date:  1965-02-15

2.  LYSOSTAPHIN: ENZYMATIC MODE OF ACTION.

Authors:  H P BROWDER; W A ZYGMUNT; J R YOUNG; P A TAVORMINA
Journal:  Biochem Biophys Res Commun       Date:  1965-04-23       Impact factor: 3.575

3.  Observations on the nature of staphylococcal infections.

Authors:  D E ROGERS
Journal:  Bull N Y Acad Med       Date:  1959-01

4.  An analysis of the effects of penicillin on an experimental infection produced by penicillin-resistant staphylococci.

Authors:  D B LOURIA; D E ROGERS
Journal:  J Lab Clin Med       Date:  1960-02

5.  Studies of microbial populations artificially localized in vivo. I. Multiplication of bacteria and distribution of drugs in agar loci.

Authors:  C A WERNER; V KNIGHT; W McDERMOTT
Journal:  J Clin Invest       Date:  1954-05       Impact factor: 14.808

6.  DELIVERY OF ANTIMICROBIAL DRUGS ACROSS INFLAMMATORY MEMBRANE IN RABBITS.

Authors:  R McCune
Journal:  J Clin Invest       Date:  1960-06       Impact factor: 14.808

7.  Lytic action of lysostaphin on susceptible and resistant strains of Staphylococcus aureus.

Authors:  W A Zygmunt; H P Browder; P A Tavormina
Journal:  Can J Microbiol       Date:  1967-07       Impact factor: 2.419

8.  Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies.

Authors:  W Schaffner; M A Melly; J H Hash; M G Koenig
Journal:  Yale J Biol Med       Date:  1967-02

9.  Microbial persistence.

Authors:  W McDERMOTT
Journal:  Yale J Biol Med       Date:  1958-02

10.  Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies.

Authors:  W Schaffner; M A Melly; M G Koenig
Journal:  Yale J Biol Med       Date:  1967-02
View more
  12 in total

Review 1.  Principles of combination therapy.

Authors:  S Levin; A A Harris
Journal:  Bull N Y Acad Med       Date:  1975-10

2.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Authors:  Caroline M Kusuma; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus.

Authors:  K E Quickel; R Selden; J R Caldwell; N F Nora; W Schaffner
Journal:  Appl Microbiol       Date:  1971-09

6.  Mutanolysin, bacteriolytic agent for cariogenic Streptococci: partial purification and properties.

Authors:  K Yokogawa; S Kawata; S Nishimura; Y Ikeda; Y Yoshimura
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

7.  Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.

Authors:  Nandini Kiri; Gordon Archer; Michael W Climo
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model.

Authors:  Irina S Barequet; Zohar Habot-Wilner; Oran Mann; Mary Safrin; Dennis E Ohman; Efrat Kessler; Mordechai Rosner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-12       Impact factor: 3.117

10.  Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.

Authors:  Irina S Barequet; Guy J Ben Simon; Mary Safrin; Dennis E Ohman; Efrat Kessler
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.